CVKD Cadrenal Therapeutics, Inc.
3,427
$0.4935
$0.0135
(2.81%)
| Watchers | 3,427 |
| 52-Wk Low | $0.36 |
| 52-Wk High | $3.14 |
| Market Cap | $7.68M |
| Volume | 30,990.00 |
| 52-Wk High | $3.14 |
| 52-Wk Low | $0.36 |
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024PR Newswire • 27 days ago
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 Cadrenal Therapeutics to Participate in Noble Capital Markets...
Share to Feed
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total...
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 21,900 shares, a...
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update PR Newswire PONTE VEDRA, Fla., March 11, 2024 PONTEVEDRA, Fla...
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference...
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of...
Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions Cadrenal Therapeutics Highlights...
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 Cadrenal Therapeutics to Participate in a Fireside Chat at the...
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference Cadrenal Therapeutics to Present at the Biotech Showcase on January...